



22<sup>st</sup>-23<sup>rd</sup> Feb. 2024 Grenoble, FR

**YRFM 2024**



## 31<sup>th</sup> Young Research Fellows Meeting

from Thursday 22 to Friday February 23, 2024

School of Medicine and Pharmacy

Domaine de la Merci, La Tronche

Amphitheater André BOUCHERLE

## **LOCAL ORGANISING COMMITTEE**

Léa LATOUR, PhD student

Mrinalini RAO, PhD student

Meven JOBIC, PhD student

Ahmad HAMMOUD, PhD student

Dr. Basile PERES

Prof. Ahcène BOUMENDJEL

## **SCIENTIFIC COMMITTEE**

Dr. Laurence LAFANECHERE

Dr. Caroline BARETTE

Dr. Joana TIMMINS

Dr. Yung-Sing WONG

Prof. Eric De FRANCO

Prof. Ahcène BOUMENDJEL

## Sponsors



## Day 1: Thursday February 22

9H - Registration

10H: Opening of 31th YRFM

**Session 1: Chair, Dr. Laurence LAFANECHERE**, CNRS, University Grenoble Alpes.

10H30 - 11H10      Plenary Lecture, **Dr. Pauline POINOT**, University of Poitiers  
*Induced-volatolomics for the exploration of biological processes*

11H10 -12H10      **Oral Communications**

OC1: **DEJEU Jérôme**. *Bio-Layer Interferometry (BLI): a useful tool to investigate the interactions between ligands (small molecules and proteins) and i-motif DNA.*

OC2: **CHAIBI Fatima-Zahra**. *Optimization of the potency of the F01, an inhibitor of 3CL<sup>pro</sup> of SARS-CoV-2 identified by an NMR-Based Screening.*

OC3: **HANOT Marie**. *New anti-virulence 2-heteroaryl-4-aminoquinolines to tackle multi-drug resistant *Pseudomonas aeruginosa*.*

12H10 -12H40      **Poster Flash**

PF1: **VEETIL Avathan**. *Discovery of indole-based inhibitors targeting the endoribonuclease IRE1.*

PF2: **BURKE Katie**. *Synthesis of narrow-spectrum antibiotics to combat the emergence of bacterial resistance.*

PF3: **CHARRIER Elise**. *Synthesis and in vitro evaluation of amino-alcohol-quinolines designed to treat non-tuberculous mycobacteria infections.*

PF4: **CURCIO Antonio**. *In silico identification of selective binders for the singular bulge region of a (3+1) hybrid G-quadruplex in the PARP1 promoter.*

PF5: **HE Ben**. *Discovery of potent IRAP inhibitors using a combination of docking and SAR.*

PF6: **TISSEUR Lhana**. *Modulation of the 4-fluorophenyl ring of the antileishmanial agent CTN1122 modifies its antiparasitic and L-CK1.2 inhibition properties*

PF7: **AYMARD Mandy**. *Synthesis of bivalent DYRK1A inhibitors to treat neurodegenerative diseases*

PF8: **LIU Yang**. *Discovery of aminothiazolone inhibitors that disrupt METTL16-RNA interaction and modulate m6A RNA modification*

12H40 - 13H45 Lunch break – Poster session

13H30 – 14H15 Interview simulations (reserved for those who asked for)

**Session 2: Chair, Dr. Caroline BARETTE**, Atomic Energy Agency (CEA), Grenoble

14H15 - 14H45 Keynote Lecture, **Dr. Viet-Khoa TRAN NGUYEN**, University Paris Cité

*A practical guide to machine-learning scoring for structure-based virtual screening*

14H45 - 15H45 **Oral Communications**

OC4: **HAUSDORFF Marcel**. *Adenosine mimetics as selective and potent inhibitors of coronavirus nsp14 N7-methyltransferases.*

OC5: **FOUGIAXIS Vasileios**. *Unveiling chemical probes of ERAP-metalloproteases through Kinetic Target-Guided Synthesis (KTGS).*

OC6: **JACQUET Ines**. *Antileishmanial SAR study of new 3-nitroimidazo[1,2-a]pyridine derivatives through TDAE-mediated modulation of position 2.*

15H45 - 16H15 Keynote Lecture, **Dr. Emmanuelle DUBOST**, University of Caen

*Design and synthesis of molecular hosts cryptophanes- application in imaging*

16H15 – 16H45 Coffee break – Poster session

**Session 3: Chair, Dr. Yung-Sing WONG**, CNRS, University Grenoble Alpes

16H45 – 17H25 Plenary Lecture, **Dr. Laurent MEIJER**, Perha Pharmaceuticals  
*Leucettinib-21, a DYRK1A kinase inhibitor drug candidate aiming at the correction of cognitive disorders in people with Down syndrome or Alzheimer's disease*

17H25 – 18H25 **Oral Communications**

OC7: **LETULLE Cécile**. *Synthesis and vectorization of novel chalcones and derivatives with anticancer activity.*

OC8: **MARCHISIO Luca**. *Design, synthesis, molecular modeling and evaluation of novel arginase inhibitors from pharmacomodulation of Piceatannol.*

OC9: **MEURILLON Virginie**. *6-Substituted quinolines as novel inhibitors of E. coli AcrAB-TolC efflux pump.*

18H25 - 18H55 Keynote Lecture, **Dr. Basile PERES**, University Grenoble Alpes  
*Pseudocyclopeptides as new Molecular Tools*

**Diner**

## Day 2: Friday February 23

### Session 4: Chair, Prof. Eric DEFRANCQ, University Grenoble Alpes

8H30 - 9H10 Plenary Lecture, **Dr. Samir MESSAOUDI**, University Paris Saclay  
*Innovative catalytic strategies for carbohydrate functionalization: applications in bioactive molecule synthesis*

9H10 - 10H30 Oral Communications

OC10: **MOSSINO DIAZ Louna**. Design, synthesis and evaluation of conjugates targeting the focal adhesion kinase and the immune checkpoint PD-1/PD-L1 to increase antitumor activity.

OC11: **ORTILLON Marine**. Design and biological evaluation of alpha/beta interface-selective CK2 kinase inhibitor.

OC12: **ROUX Hugo**. From Anti-Rhinovirus to Broad-Spectrum Enterovirus Inhibitors.

OC13: **RUGGIERI Francesca**. Putting Nature Back into Drug Discovery

10H30 - 11H Coffee break – Poster Session

### Session 5: Chair, Dr. Basile PERES, University Grenoble Alpes

11H – 11H30 Keynote Lecture, **Dr. Cyrille BOTTE**, Institute of Advanced Biosciences, Grenoble.  
*Using Mass spectrometry-based lipidomics to dissect host-pathogens metabolic interactions.*

11H30 – 12H10 Oral communications

OC14: **ROUSSEL Jean**. Haspin kinase as a model for obtaining selective inhibitors using peptide mimetic substrates.

OC15: **TRINCAS Massimo**. Identification of G-quadruplex binding ligands via DNA encoded combinatorial library (DEL) selections

12H10 - 12H50 Plenary Lecture, **Prof. Emerson FERREIRA QUEIROZ**, University of Geneva  
*From the discovery of bioactive natural products to the development of innovative strategies for their chemo-diversification and generation of potential new leads*

12H40 – 13H Concluding Remarks – Awards

**Lunch**